The low survival rate of adult T-cell leukemia/lymphoma (ATL) underscores the critical need for innovative therapeutic agents. While the pharmacokinetics of HDACis have been documented in several hematological neoplasms, there is a notable gap in research regarding their activity against ATL. Given that hypoxia can induce unpredictable effects on lymphoma cells, this study aimed to evaluate the toxic effects of MS-275 and novel analogs on ATL cells in hypoxic condition for the first time. Protein-protein interaction and gene set enrichment analyses were performed, the expression of HIF1A and downstream targets were assessed, and molecular docking was conducted on MS-275 and novel analogs with HIF-1α. For studies, at first benzamide analogs of MS-275 were synthesized and then, viability of MT-2 cells was evaluated in hypoxic condition. Enrichment analyses confirmed the involvement of hub genes in HIF-1 signaling pathway and volcano plot revealed over expression of HIF1A, GAL3ST1 and CD274. Molecular docking indicated favorable interaction between MS-275 and analogs with HIF-1α PAS-B domain. Results of alamarBlue assay demonstrated that MS-275 and analogs significantly ( < 0.001) reduced viability of MT-2 cells in hypoxic condition. Findings of the present study hold promise for developing new drugs targeting hypoxia-induced changes in ATL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1120009X.2024.2411825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA.
Sci Rep
January 2025
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, N-7491, Trondheim, Norway.
The cytotoxic mechanisms of thymidylate synthase inhibitors, such as the multitarget antifolate pemetrexed, are not yet fully understood. Emerging evidence indicates that combining pemetrexed with histone deacetylase inhibitors (HDACi) may enhance therapeutic efficacy in non-small cell lung cancer (NSCLC). To explore this further, A549 NSCLC cells were treated with various combinations of pemetrexed and the HDACi MS275 (Entinostat), and subsequently assessed for cell viability, cell cycle changes, and genotoxic markers.
View Article and Find Full Text PDFDeveloping new drugs for adult T-cell leukemia/lymphoma by targeting hypoxia: insights from toxicity of MS-275 and its analogs.
J Chemother
October 2024
Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
The low survival rate of adult T-cell leukemia/lymphoma (ATL) underscores the critical need for innovative therapeutic agents. While the pharmacokinetics of HDACis have been documented in several hematological neoplasms, there is a notable gap in research regarding their activity against ATL. Given that hypoxia can induce unpredictable effects on lymphoma cells, this study aimed to evaluate the toxic effects of MS-275 and novel analogs on ATL cells in hypoxic condition for the first time.
View Article and Find Full Text PDFEntinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
Oncologist
September 2024
Department of Medicine, Division of Hematology Oncology, Columbia University Irving Medical Center, New York, NY, United States.
Article Synopsis
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but increasingly common cancers that may require systemic therapy due to their metastatic nature or recurrence after surgery, with somatostatin analogs being typical first-line treatments.
- This study assessed the effectiveness and safety of a histone deacetylase (HDAC) inhibitor called entinostat in patients with relapsed or refractory abdominal NETs, primarily measuring the objective response rate and tumor growth rates before and after treatment.
- Out of 5 enrolled patients, only 4 were evaluable; they all experienced stable disease for extended periods, and patients showed significantly reduced tumor growth while on entinostat.
Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.
Am J Cancer Res
November 2022
Department of Pathology, The University of Iowa Iowa City, IA 52242, USA.
Article Synopsis
- - Uterine endometrial cancer (EC) is increasingly prevalent, and traditional hormone therapy using progesterone is effective for initial treatment, but many patients develop resistance over time, leading to poor outcomes for PR-negative tumors.
- - Histone deacetylase inhibitors (HDACi), like entinostat and romidepsin, have shown promise in reversing the downregulation of progesterone receptors (PR) in EC cells, enhancing their responsiveness to progestin therapy, and demonstrating tumor growth inhibition in models.
- - A clinical trial supported by these findings indicated that while entinostat combined with MPA (a progestin) reduced tumor proliferation markers, romidepsin significantly improved treatment effectiveness and up
Hyperacetylation of the C-terminal domain of p53 inhibits the formation of the p53/p21 complex.
Biochem Biophys Res Commun
December 2022
Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea. Electronic address:
Given our previous finding that certain tumor-suppressing functions of p53 are exerted by the p53/p21 complex, rather than p53 alone, cells may have a system to regulate the p53/p21 interaction. As p53 binds to p21 via its C-terminal domain, which contains acetylable lysine residues, we investigated whether the C-terminal acetylation of p53 influences the p53/p21 interaction. Indeed, the p53/p21 interaction was reduced when various types of cells (HCT116 colon cancer, A549 lung cancer, and MCF7 breast cancer cells) were treated with MS-275, an inhibitor of SIRT1 (a p53 deacetylase), or with SIRT1-targeting small interfering RNAs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!